Browsing by Author Wanders, J.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jump to: Α Β Γ Δ Ε Ζ Η Θ Ι Κ Λ Μ Ν Ξ Ο Π Ρ Σ Τ Υ Φ Χ Ψ Ω
or enter first few letters:  
View Option
Showing results 1 to 12 of 12
TitleAuthor(s)Issue date???itemlist.???
Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical studyGamucci, T.; Paridaens, R.; Heinrich, B.; Schellens, J. H.; Pavlidis, N.; Verweij, J.; Sessa, C.; Kaye, S.; Roelvink, M.; Wanders, J.; Hanauske, A.24-Nov-2015-
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)Pavlidis, N.; Aamdal, S.; Awada, A.; Calvert, H.; Fumoleau, P.; Sorio, R.; Punt, C.; Verweij, J.; van Oosterom, A.; Morant, R.; Wanders, J.; Hanauske, A. R.24-Nov-2015-
Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)Cerny, T.; Kaplan, S.; Pavlidis, N.; Schoffski, P.; Epelbaum, R.; van Meerbeek, J.; Wanders, J.; Franklin, H. R.; Kaye, S.24-Nov-2015-
Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groupsMcLeod, H. L.; Murray, L. S.; Wanders, J.; Setanoians, A.; Graham, M. A.; Pavlidis, N.; Heinrich, B.; ten Bokkel Huinink, W. W.; Wagener, D. J.; Aamdal, S.; Verweij, J.24-Nov-2015-
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies GroupBriasoulis, E.; Judson, I.; Pavlidis, N.; Beale, P.; Wanders, J.; Groot, Y.; Veerman, G.; Schuessler, M.; Niebch, G.; Siamopoulos, K.; Tzamakou, E.; Rammou, D.; Wolf, L.; Walker, R.; Hanauske, A.24-Nov-2015-
Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials GroupHanauske, A. R.; Catimel, G.; Aamdal, S.; ten Bokkel Huinink, W.; Paridaens, R.; Pavlidis, N.; Kaye, S. B.; te Velde, A.; Wanders, J.; Verweij, J.24-Nov-2015-
Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials GroupVerweij, J.; Wanders, J.; Nielsen, A. L.; Pavlidis, N.; Calabresi, F.; ten Bokkel Huinink, W.; Bruntsch, U.; Piccart, M.; Franklin, H.; Kaye, S. B.24-Nov-2015-
Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancerKerbrat, P.; Dieras, V.; Pavlidis, N.; Ravaud, A.; Wanders, J.; Fumoleau, P.24-Nov-2015-
Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG)Chollet, P.; Schoffski, P.; Weigang-Kohler, K.; Schellens, J. H.; Cure, H.; Pavlidis, N.; Grunwald, V.; De Boer, R.; Wanders, J.; Fumoleau, P.24-Nov-2015-
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studiesSchellens, J. H.; Heinrich, B.; Lehnert, M.; Gore, M. E.; Kaye, S. B.; Dombernowsky, P.; Paridaens, R.; van Oosterom, A. T.; Verweij, J.; Loos, W. J.; Calvert, H.; Pavlidis, N.; Cortes-Funes, H.; Wanders, J.; Roelvink, M.; Sessa, C.; Selinger, K.; Wissel, P. S.; Gamucci, T.; Hanauske, A. R.24-Nov-2015-
Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9Schellens, J. H.; Dombernowsky, P.; Cassidy, J.; Epelbaum, R.; Dirix, L.; Cox, E. H.; Wanders, J.; Calabresi, F.; Paridaens, R.; Monfardini, S.; Wolff, J.; Loos, W. J.; Verweij, J.; Pavlidis, N.; Hanauske, A. R.24-Nov-2015-
Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials GroupKaplan, S.; Hanauske, A. R.; Pavlidis, N.; Bruntsch, U.; te Velde, A.; Wanders, J.; Heinrich, B.; Verweij, J.24-Nov-2015-